UPDATE: Threshold Pharmaceuticals (THLD) Higher After Lazard Capital More Than Doubles Price Target
Tweet
Share
E-mail
Get Alerts THLD Hot Sheet
Price: $0.54 --0%
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 10
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 10
Join SI Premium – FREE
(Updated - March 29, 2012 9:00 AM EDT)
Threshold Pharmaceuticals (NASDAQ: THLD) is seeing pre-open interest Thursday after Lazard Capital more than doubled its price target on the stock from $7 to $15 while maintaining a Buy rating.
The new price target represents 88 percent upside from Wednesday's close.
Lazard's analyst notes that updated Phase 2b data at AACR will position TH-302 as one of leading pancreatic cancer clinical candidates. Data on TH-302 will be presented April 2 at 11:30am EST at AACR's late-breaking clinical trial session. The late-breaking oral presentation will report efficacy and safety data from the randomized Phase 2b trial of TH-302 plus gemcitabine versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. Data may show a more substantive view of survival trends, according to the firm.
For an analyst ratings summary and ratings history on Threshold Pharmaceuticals click here. For more ratings news on Threshold Pharmaceuticals click here.
Shares of Threshold Pharmaceuticals closed at $7.96 yesterday.
Threshold Pharmaceuticals (NASDAQ: THLD) is seeing pre-open interest Thursday after Lazard Capital more than doubled its price target on the stock from $7 to $15 while maintaining a Buy rating.
The new price target represents 88 percent upside from Wednesday's close.
Lazard's analyst notes that updated Phase 2b data at AACR will position TH-302 as one of leading pancreatic cancer clinical candidates. Data on TH-302 will be presented April 2 at 11:30am EST at AACR's late-breaking clinical trial session. The late-breaking oral presentation will report efficacy and safety data from the randomized Phase 2b trial of TH-302 plus gemcitabine versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. Data may show a more substantive view of survival trends, according to the firm.
For an analyst ratings summary and ratings history on Threshold Pharmaceuticals click here. For more ratings news on Threshold Pharmaceuticals click here.
Shares of Threshold Pharmaceuticals closed at $7.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Downgrades Saipem (SPM:IM) (SAPMY) to Hold
- ONE Gas Inc. (OGS) PT Raised to $64 at Mizuho
- Danone SA (BN:FP) (DANOY) PT Raised to EUR72 at Stifel
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot CommentsRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
